Clinical trial
Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With…
NCT00499655 · City of Hope Medical Center, Other · Completed
Key facts
| NCT number | NCT00499655 |
|---|---|
| Title | Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer |
| Official title | A Randomized, Placebo-Controlled Phase II Clinical Trial of Combination Erlotinib (Tarceva) and Celecoxib (Celebrex) Versus Erlotinib (Tarceva)/Placebo in Advanced Non-Small Cell Lung Cancer Patients |
| Lead sponsor | City of Hope Medical Center, Other |
| Collaborators | OSI Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Drug, Genetic, Other |
| Interventions | erlotinib hydrochloride, celecoxib, placebo, laboratory biomarker analysis, immunohistochemistry staining method, fluorescence in situ hybridization, mutation analysis, protein expression analysis, gene expression analysis |
| Enrollment | 107 |
| Start date | Nov 1, 2007 |
| Primary completion | Dec 1, 2016 |
| Completion | Dec 1, 2016 |
| First posted | Jul 11, 2007 |
| Last update posted | Mar 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: